QLGN Stock Overview
A clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Qualigen Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.90 |
| 52 Week High | US$30.50 |
| 52 Week Low | US$3.34 |
| Beta | 0.15 |
| 1 Month Change | -19.27% |
| 3 Month Change | -53.29% |
| 1 Year Change | -86.55% |
| 3 Year Change | -99.40% |
| 5 Year Change | n/a |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M
Aug 16Qualigen Therapeutics files mixed shelf offering of up to $150M
Jul 29Qualigen partners Hande Sciences to support its application enabling studies for QN-302
Jul 06Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?
Mar 08
We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate
Nov 23Shareholder Returns
| QLGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.8% | -3.6% | -2.4% |
| 1Y | -86.6% | -2.6% | 23.4% |
Return vs Industry: QLGN underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: QLGN underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| QLGN volatility | |
|---|---|
| QLGN Average Weekly Movement | 15.9% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: QLGN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: QLGN's weekly volatility has decreased from 22% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 4 | Kevin Richardson | www.qlgntx.com |
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors.
Qualigen Therapeutics, Inc. Fundamentals Summary
| QLGN fundamental statistics | |
|---|---|
| Market cap | US$2.87m |
| Earnings (TTM) | -US$7.86m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs QLGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QLGN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$2.55m |
| Gross Profit | -US$2.55m |
| Other Expenses | US$5.31m |
| Earnings | -US$7.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.67 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -67.0% |
How did QLGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:41 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Qualigen Therapeutics, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| David Bautz | Zacks Small-Cap Research |